Abstract

Abs are glycoproteins that carry a conserved N-linked carbohydrate attached to the Fc whose presence and fine structure profoundly impacts on their in vivo immunogenicity, pharmacokinetics, and functional attributes. The host cell line used to produce IgG plays a major role in this glycosylation, as different systems express different glycosylation enzymes and transporters that contribute to the specificity and heterogeneity of the final IgG-Fc glycosylation profile. In this study, we compare two panels of glycan-adapted IgG1-Fc mutants expressed in either the human endothelial kidney 293-F or Chinese hamster ovary-K1 systems. We show that the types of N-linked glycans between matched pairs of Fc mutants vary greatly and in particular, with respect, to sialylation. These cell line effects on glycosylation profoundly influence the ability of the engineered Fcs to interact with either human or pathogen receptors. For example, we describe Fc mutants that potently disrupted influenza B-mediated agglutination of human erythrocytes when expressed in Chinese hamster ovary-K1, but not in human endothelial kidney 293-F cells.

Highlights

  • All the mutants migrated on SDS-PAGE with the expected molecular weights for their glycosylation or disulfide bonding states (Fig. 4) and as previously described for the same mutants expressed by Chinese hamster ovary (CHO)-K1 cells [30, 31]

  • In an earlier study with CHO-K1 cells, we demonstrated that a proportion of molecules in which the tailpiece Asn-563 glycan was substituted for alanine ran as multimers in solution when examined by size exclusion HPLC [31]

  • We have shown using CHO-K1 cells that the structure and effector function of human IgG1-Fc can be profoundly altered by the addition or removal of N-linked glycosylation [30, 31]

Read more

Summary

Objectives

The aim of the current study was to reveal possible variation in functional glycosylation related to differences in two host cell lines, CHO-K1 and HEK 293-F, as Abs and Fc fusions are the fastest growing therapeutic class in the pharmaceutical industry (34, 47, 48)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call